Abstract
γδ T cells are capable of recognizing tumor cells and exert potent cellular cytotoxicity against a large range of tumors, including colon cancer. However, tumors utilize numerous strategies to escape recognition or killing by patrolling γδ T cells, such a downregulation of NKG2D ligands, MICA/B and ULBPs. Therefore, the combined upregulation of T-cell receptorand NKG2D ligands on tumor cells and induction of NKG2D expression on γδ T cells may greatly enhance tumor killing and unlock the functions of γδ T cells. Here, we briefly review current data on the mechanisms of γδ T-cell recognition and killing of colon cancer cells and propose that γδ T cells may represent a promising target for the design of novel and highly innovative immunotherapy in patients with colon cancer.
Original language | English |
---|---|
Pages (from-to) | 989-999 |
Number of pages | 11 |
Journal | Immunotherapy |
Volume | 6 |
Issue number | 9 |
DOIs | |
Publication status | Published - Sep 1 2014 |
Keywords
- colon cancer
- HDAC inhibitor
- immune surveillance
- immunotherapy
- MICA/B
- NKG2D-mediated killing
- Vγ9Vγ2 T cells
ASJC Scopus subject areas
- Immunology and Allergy
- Oncology
- Immunology
- Medicine(all)